Introduction {#tca13144-sec-0005}
============

Esophageal cancer is ranked as one of the most common digestive system cancers worldwide[1](#tca13144-bib-0001){ref-type="ref"}, [2](#tca13144-bib-0002){ref-type="ref"} and as the seventh most frequent cause of cancer‐related death for males in the United States.[3](#tca13144-bib-0003){ref-type="ref"}Surgical resection has been the mainstay of therapy for localized operable esophageal cancer.[4](#tca13144-bib-0004){ref-type="ref"}However, the therapeutic strategies for patients with advanced‐stage esophageal cancer remain controversial, especially for those involving nonregional lymph nodes.[5](#tca13144-bib-0005){ref-type="ref"}, [6](#tca13144-bib-0006){ref-type="ref"}, [7](#tca13144-bib-0007){ref-type="ref"}, [8](#tca13144-bib-0008){ref-type="ref"}

The latest eighth edition of the Union for International Cancer Control--American Joint Committee on Cancer (UICC--AJCC) TNM staging system for esophageal cancer and the Eleventh edition of the Japanese Classification of Esophageal Cancer by the Japan Esophageal Society (JES) are the two major classifications widely accepted for staging of esophageal cancer.[9](#tca13144-bib-0009){ref-type="ref"}, [10](#tca13144-bib-0010){ref-type="ref"}, [11](#tca13144-bib-0011){ref-type="ref"}, [12](#tca13144-bib-0012){ref-type="ref"} However, these two major staging systems have not reached a consensus on the prognostic significance of regional and nonregional lymph node involvement in thoracic esophageal cancer, or more specifically on the implication of supraclavicular node metastasis. Recently, many Japanese surgeons have proposed that the supraclavicular nodes should be classified as regional ones for upper thoracic esophageal cancer (UTEC)[5](#tca13144-bib-0005){ref-type="ref"}, [8](#tca13144-bib-0008){ref-type="ref"}, [13](#tca13144-bib-0013){ref-type="ref"} which was supported by some Asian and Western surgeons.[14](#tca13144-bib-0014){ref-type="ref"}, [15](#tca13144-bib-0015){ref-type="ref"} In fact, involvement of celiac lymph nodes (nodal station 20) was previously classified as metastatic (M1a) disease for lower thoracic esophageal cancer (LTEC) in the sixth edition of the AJCC staging system;[5](#tca13144-bib-0005){ref-type="ref"} similarly, involvement of the supraclavicular lymph nodes (nodal station 1) was designated as M1a disease for UTEC.[7](#tca13144-bib-0007){ref-type="ref"}, [16](#tca13144-bib-0016){ref-type="ref"} However, in later editions of the AJCC staging system, celiac lymph nodes were redefined as regional ones for LTEC, whereas supraclavicular lymph nodes remained as nonregional ones for UTEC.[16](#tca13144-bib-0016){ref-type="ref"}, [17](#tca13144-bib-0017){ref-type="ref"}, [18](#tca13144-bib-0018){ref-type="ref"}, [19](#tca13144-bib-0019){ref-type="ref"} Subsequently, celiac node involvement was reclassified as nodal (N) disease, while supraclavicular node involvement remained as metastatic (M1) disease. Therefore, it is important to ask if supraclavicular and celiac node metastasis can be classified into the M and N staging parameters respectively, which definitely affects the treatment for esophageal cancer.

In the present study, we reevaluated the prognostic significance of supraclavicular and celiac lymph node metastasis and assessed the treatment strategies for patients with either metastasis using the Surveillance, Epidemiology, and End Results (SEER) database.

Methods {#tca13144-sec-0006}
=======

Patients and population cohort {#tca13144-sec-0007}
------------------------------

The National Cancer Institute's SEER database was utilized for the present study with information of cancer patients.[20](#tca13144-bib-0020){ref-type="ref"} Data for patients with esophageal cancer diagnosed between 2004 and 2015 were extracted from the SEER database with eligibility criteria as follows: (i) age older than 18 years and histologically confirmed cancer arising from the esophagus (ICD‐O‐3 codes: 8000--8576, 8940--8950, 8980--8981); (ii) primary tumor located in the upper or lower thoracic esophagus;[21](#tca13144-bib-0021){ref-type="ref"} (iii) survival time ≥ 3 months. The Collaborative Stage Data Collection System codes at DX (Distant) and Lymph Nodes were used to query cases with celiac, supraclavicular or regional lymph node metastasis. All eligible patients were staged according to the sixth edition of the AJCC staging manual.[22](#tca13144-bib-0022){ref-type="ref"}

Statistical analysis {#tca13144-sec-0008}
--------------------

The primary outcomes were overall survival (OS) and cancer‐specific survival (CSS). OS was defined as the interval between the diagnosis of cancer and death or last follow‐up. CSS was measured from the date of initial treatment to death from esophageal cancer. Prognostic factors were compared by the log‐rank test and Kaplan‐Meier methods. The chi‐squared test was used to compare categorical variables and Student's *t*‐test was employed for continuous data. Multivariate analyses were performed by Cox regression. Hazard ratios (HR) with 95% confidence intervals (CI) were used to quantify the strength of the association between predictors and survival. All statistical analyses were performed using R software version 3.4.4 (Institute for Statistics and Mathematics, Vienna, Austria). A two‐tailed *P*‐value \<0.05 was considered statistically significant.

Results {#tca13144-sec-0009}
=======

General information {#tca13144-sec-0010}
-------------------

The entire cohort consisted of 6178 patients with thoracic esophageal cancer, including 5803 patients with LTEC and 375 patients with UTEC. Table [1](#tca13144-tbl-0001){ref-type="table"} lists the demographic parameters of all patients. Among patients with LTEC, there were 492 patients (8.5%) with supraclavicular lymph node involvement and 588 patients (10.1%) with celiac lymph node involvement. Among patients with UTEC, there were 25 patients (6.7%) with supraclavicular lymph node involvement and 27 patients with celiac lymph node involvement (7.2%).

###### 

Characteristics of patients in the entire cohort

  Clinicopathological characteristics Stratified by Site                                                 Lower           Upper           *P*
  -------------------------------------------------------- --------------------------------------------- --------------- --------------- ---------
  Number of patients                                                                                     5803            375             
  Nodal status (%)                                         Regional node metastasis                      4723 (81.4)     323 (86.1)      0.067
                                                           Supraclavicular node (station 1) metastasis   492 (8.5)       25 (6.7)        
                                                           Celiac node (station 20) metastasis           588 (10.1)      27 (7.2)        
  Age at diagnosis (mean \[SD\])                                                                         64.83 (11.10)   65.35 (10.73)   0.377
  Sex (%)                                                  Female                                        816 (14.1)      119 (31.7)      \<0.001
                                                           Male                                          4987 (85.9)     256 (68.3)      
  CHSDA region (%)                                         East                                          2224 (38.3)     163 (43.5)      0.167
                                                           NP                                            743 (12.8)      39 (10.4)       
                                                           PC                                            2594 (44.7)     161 (42.9)      
                                                           SW                                            242 (4.2)       12 (3.2)        
  Marital status (%)                                       Married (including common law)                3850 (66.3)     183 (48.8)      \<0.001
                                                           Separated/widowed/divorced                    1159 (20.0)     117 (31.2)      
                                                           Single (never married)                        794 (13.7)      75 (20.0)       
  Histology type (%)                                       Adenocarcinoma                                4372 (75.3)     32 (8.5)        \<0.001
                                                           Squamous cell carcinoma                       816 (14.1)      328 (87.5)      
                                                           Others                                        615 (10.6)      15 (4.0)        
  T stage (%)                                              T1                                            819 (14.1)      58 (15.5)       \<0.001
                                                           T2                                            805 (13.9)      50 (13.3)       
                                                           T3                                            3544 (61.1)     169 (45.1)      
                                                           T4                                            635 (10.9)      98 (26.1)       
  N stage (%)                                              N0                                            2263 (39.0)     116 (30.9)      0.002
                                                           N1                                            3540 (61.0)     259 (69.1)      
  Tumor size (%)                                           ≤5 cm                                         2562 (44.1)     169 (45.1)      0.809
                                                           \>5 cm                                        1603 (27.6)     106 (28.3)      
                                                           Unknown                                       1638 (28.2)     100 (26.7)      
  Surgery (%)                                              No                                            2949 (50.8)     325 (86.7)      \<0.001
                                                           Yes                                           2854 (49.2)     50 (13.3)       
  Surgery type (%)                                         Esophagectomy                                 2827 (48.7)     44 (11.7)       \<0.001
                                                           Endoscopic treatment                          27 (0.5)        6 (1.6)         
  Radiotherapy (%)                                         No                                            1311 (22.6)     69 (18.4)       0.068
                                                           Yes                                           4492 (77.4)     306 (81.6)      
  Chemotherapy (%)                                         No/unknown                                    944 (16.3)      75 (20.0)       0.069
                                                           Yes                                           4859 (83.7)     300 (80.0)      
  Race (%)                                                 White                                         5293 (91.2)     257 (68.5)      \<0.001
                                                           Black                                         277 (4.8)       72 (19.2)       
                                                           Others                                        233 (4.0)       46 (12.3)       
  Grade (%)                                                G1                                            240 (4.1)       22 (5.9)        0.002
                                                           G2                                            2230 (38.4)     175 (46.7)      
                                                           G3                                            3227 (55.6)     173 (46.1)      
                                                           G4                                            106 (1.8)       5 (1.3)         
  Diagnosed year (%)                                       2004--2009                                    2446 (42.2)     133 (35.5)      0.013
                                                           2010--2015                                    3357 (57.8)     242 (64.5)      

CHSDA, Contract Health Service Delivery Areas; NP, Northern Plains; PC, Pacific Coast; SW, South West; SD, standard deviation.

Status of lymph node metastases and survival rates {#tca13144-sec-0011}
--------------------------------------------------

As shown in Figure [1](#tca13144-fig-0001){ref-type="fig"}a,b, the prognostic impact of different nodal status on UTEC was compared. In this subgroup, there was no significant difference in OS (*P* = 0.56; Fig [1](#tca13144-fig-0001){ref-type="fig"}a) and CSS (*P* = 0.36; Fig [1](#tca13144-fig-0001){ref-type="fig"}b) between UTEC with regional node metastasis and those with supraclavicular or celiac node metastasis. In contrast, Figure [1](#tca13144-fig-0001){ref-type="fig"}c,d presents the prognoses of LTEC stratified by nodal status. In this subgroup, significantly worse OS (*P* \< 0.0001; Fig [1](#tca13144-fig-0001){ref-type="fig"}c) and CSS (*P* \< 0.0001; Fig [1](#tca13144-fig-0001){ref-type="fig"}d) were observed in LTEC with supraclavicular node metastasis compared to those with regional or celiac node metastasis.

![Prognostic impact of different nodal status on patients with thoracic esophageal cancer. (**a**) Overall Survival (OS) for upper thoracic esophageal cancer (UTEC) involving regional nodes (UR), supraclavicular nodes (U1) or celiac nodes (U20). (**b**) Cancer‐specific survival (CSS) for UTEC involving UR, U1 or U20 nodes. (![](TCA-10-1725-g006.jpg "image")) Group=UR, (![](TCA-10-1725-g007.jpg "image")) Group=U20, and (![](TCA-10-1725-g008.jpg "image")) Group=U1. (**c**) OS for lower thoracic esophageal cancer (LTEC) involving regional nodes (LR), supraclavicular nodes (L1) or celiac nodes (L20). (**d**) CSS for LTEC involving LR, L1 or L20 nodes. (![](TCA-10-1725-g009.jpg "image")) Group=LR, (![](TCA-10-1725-g010.jpg "image")) Group=L20, and (![](TCA-10-1725-g011.jpg "image")) Group=L1.](TCA-10-1725-g001){#tca13144-fig-0001}

Univariate and multivariate analysis of prognostic factors {#tca13144-sec-0012}
----------------------------------------------------------

As for the OS and CSS of LTEC, univariate analysis identified 13 significant risk factors, including nodal status (supraclavicular and celiac), surgery, chemotherapy and radiotherapy (Table [S1](#tca13144-supitem-0001){ref-type="supplementary-material"}).

In the multivariate analysis, supraclavicular node metastasis was shown to be a significant independent predictor of both OS (HR, 1.19; 95% CI: 1.06--1.34; *P* = 0.004) and CSS (HR, 1.17; 95% CI: 1.02--1.33; *P* = 0.02) for LTEC (Table [S2](#tca13144-supitem-0001){ref-type="supplementary-material"}). In addition, surgery (OS, HR: 0.47; 95% CI: 0.43--0.5; *P* \< 0.001; CSS, HR: 0.45; 95% CI: 0.42--0.49; *P* \< 0.001), chemotherapy (OS, HR: 0.58; 95% CI: 0.52--0.63; *P* \< 0.001; CSS, HR: 0.58; 95% CI: 0.52--0.65; *P* \< 0.001) and radiotherapy (OS, HR: 0.81; 95% CI: 0.74--0.88; *P* \< 0.001; CSS, HR: 0.81; 95% CI: 0.74--0.9; *P* \< 0.001) were independent predictors of prognoses.

For patients with UTEC, eight significant risk factors were identified in univariate analysis for OS and CSS (Table [S3](#tca13144-supitem-0001){ref-type="supplementary-material"}). Notably, neither supraclavicular nor celiac nodal location was an independent predictor of OS and CSS for UTEC.

In the multivariate analysis, surgery (OS, HR: 0.63; 95% CI: 0.42--0.95; *P* = 0.026; CSS, HR: 0.6; 95% CI: 0.37--0.96; *P* = 0.034) and chemotherapy (OS, HR: 0.37;95% CI: 0.26--0.52; *P* \< 0.001; CSS, HR: 0.33; 95% CI: 0.21--0.51; *P* \< 0.001) were significant independent predictors of both OS and CSS for UTEC (Table [S4](#tca13144-supitem-0001){ref-type="supplementary-material"}).

Nodal status and therapeutic role of treatment {#tca13144-sec-0013}
----------------------------------------------

Figures [2](#tca13144-fig-0002){ref-type="fig"} and [3](#tca13144-fig-0003){ref-type="fig"} exhibit the therapeutic role of surgery in patients with UTEC (Fig [2](#tca13144-fig-0002){ref-type="fig"}a,d) and LTEC (Fig [3](#tca13144-fig-0003){ref-type="fig"}a,d).Surgery was not associated with increased OS (surgery vs. nonsurgery: 50.00% *vs*. 10.38%; *P* = 0.11; Fig [2](#tca13144-fig-0002){ref-type="fig"}a) or CSS (surgery vs. nonsurgery: 100.00% vs. 25.11%; *P* = 0.11; Fig [2](#tca13144-fig-0002){ref-type="fig"}b) for UTEC with celiac node metastasis. Similar results are displayed in Figure [2](#tca13144-fig-0002){ref-type="fig"}c,d which demonstrate that surgery did not improve the OS (surgery vs. nonsurgery: 0.00% vs. 12.20%; *P* = 0.635) or CSS (surgery vs. nonsurgery: 0.00% vs. 15.30%; *P* = 0.513) for UTEC with supraclavicular node metastasis. In contrast, significantly better OS (surgery vs. nonsurgery: 25.40% vs. 5.80%; *P* \< 0.001) and CSS (surgery vs. nonsurgery: 31.40% vs. 7.90%; *P* \< 0.001) were observed in LTEC with celiac node metastasis, as shown in Figure [3](#tca13144-fig-0003){ref-type="fig"}a,b. In addition, surgery was also associated with increased OS (surgery vs. nonsurgery: 27.00% vs. 6.10%; *P* \< 0.001; Fig [3](#tca13144-fig-0003){ref-type="fig"}c) and CSS (surgery vs. nonsurgery: 42.70% vs. 9.10%; *P* \< 0.11; Fig [3](#tca13144-fig-0003){ref-type="fig"}d) for LTEC with supraclavicular node metastasis.

![Prognostic impact of surgery on patients with upper thoracic esophageal cancer (UTEC). (**a**, **b**) Overall survival (OS) and cancer‐specific survival (CSS) for UTEC with celiac node metastasis. (**c**, **d**) OS and CSS for UTEC with supraclavicular node metastasis. (![](TCA-10-1725-g012.jpg "image")) surgery=No, and (![](TCA-10-1725-g013.jpg "image")) surgery=Yes.](TCA-10-1725-g002){#tca13144-fig-0002}

![Prognostic impact of surgery on patients with lower thoracic esophageal cancer (LTEC). (**a**, **b**) Overall survival (OS) and cancer‐specific survival (CSS) for LTEC with celiac node metastasis. (**c**, **d**) OS and CSS for LTEC with supraclavicular node metastasis. (![](TCA-10-1725-g014.jpg "image")) surgery=No, and (![](TCA-10-1725-g015.jpg "image")) surgery=Yes.](TCA-10-1725-g003){#tca13144-fig-0003}

Figures [4](#tca13144-fig-0004){ref-type="fig"} and [5](#tca13144-fig-0005){ref-type="fig"} present the prognostic impact of radiotherapy on patients with UTEC (Fig [4](#tca13144-fig-0004){ref-type="fig"}a,d) and LTEC (Fig [5](#tca13144-fig-0005){ref-type="fig"}a,d), respectively. Significantly better OS (radiotherapy vs. nonradiotherapy: 17.20% vs. 0.00%; *P* \< 0.001; Fig [4](#tca13144-fig-0004){ref-type="fig"}a) and CSS (radiotherapy vs. nonradiotherapy: 15.60% vs. 0.00%; *P* \< 0.001; Fig [4](#tca13144-fig-0004){ref-type="fig"}b) were observed in patients with celiac node metastasis who underwent radiotherapy. Interestingly, there was a significant difference in OS (radiotherapy vs. nonradiotherapy: 15.90% vs. 0.00%; *P* = 0.012; Fig [4](#tca13144-fig-0004){ref-type="fig"}c) but not in CSS (radiotherapy vs. nonradiotherapy: 17.70% vs. 0.00%; *P* = 0.075; Fig [4](#tca13144-fig-0004){ref-type="fig"}d) between radiotherapy and nonradiotherapy in UTEC with supraclavicular node metastasis. Meanwhile, radiotherapy was associated with improved OS (radiotherapy vs. nonradiotherapy: 14.50% vs. 4.20%; *P* \< 0.001; Fig [5](#tca13144-fig-0005){ref-type="fig"}a) and CSS (radiotherapy vs. nonradiotherapy: 18.90% vs. 5.50%; *P* \< 0.001; Fig [5](#tca13144-fig-0005){ref-type="fig"}b) for LTEC with celiac node metastasis. Similar results were also observed in LTEC with supraclavicular node metastasis (OS: radiotherapy vs. nonradiotherapy: 11.40% vs. 5.00%; *P* \< 0.001; Fig [5](#tca13144-fig-0005){ref-type="fig"}c; CSS: radiotherapy vs. nonradiotherapy: 14.90% vs. 11.90%; *P* = 0.004; Fig [5](#tca13144-fig-0005){ref-type="fig"}d).

![Prognostic impact of radiotherapy on patients with upper thoracic esophageal cancer. (**a**, **b**) Overall survival (OS) and cancer‐specific survival (CSS) for UTEC with celiac node metastasis. (**c**, **d**) OS and CSS for UTEC with supraclavicular node metastasis. (![](TCA-10-1725-g016.jpg "image")) radiotherapy=No, and (![](TCA-10-1725-g017.jpg "image")) radiotherapy=Yes.](TCA-10-1725-g004){#tca13144-fig-0004}

![Prognostic impact of radiotherapy on patients with lower thoracic esophageal cancer (LTEC). (**a**, **b**) OS and CSS for LTEC with celiac node metastasis. (**c**, **d**) OS and CSS for LTEC with supraclavicular node metastasis. (![](TCA-10-1725-g018.jpg "image")) radiotherapy=No, and (![](TCA-10-1725-g019.jpg "image")) radiotherapy=Yes.](TCA-10-1725-g005){#tca13144-fig-0005}

Discussion {#tca13144-sec-0014}
==========

Despite progress in esophageal cancer staging systems, the sixth edition of the AJCC staging system has continued to be the most widely used in China. However, the prognostic impact and therapeutic strategies for esophageal cancer with supraclavicular node metastasis remain controversial. As mentioned above, the implication of supraclavicular node metastasis in the AJCC and JES systems is very different. The AJCC TNM classification defines lymph nodes located in the defined area as "regional lymph nodes" regardless of the tumor location. Metastasis to lymph nodes other than regional lymph nodes, especially supraclavicular nodes, is categorized as M1.[23](#tca13144-bib-0023){ref-type="ref"} In the latest JES classification, regional nodes are subgrouped into groups 1 to 4 in five different patterns according to the main tumor location.[24](#tca13144-bib-0024){ref-type="ref"} In particular, supraclavicular nodes are classified as group 3 nodes for LTEC.[24](#tca13144-bib-0024){ref-type="ref"} Because group 3 nodes are the most distant regional nodes, proposals for their selective dissection have been reported.[25](#tca13144-bib-0025){ref-type="ref"}, [26](#tca13144-bib-0026){ref-type="ref"}, [27](#tca13144-bib-0027){ref-type="ref"} On the other hand, supraclavicular nodes are classified as group 2 for UTEC,[24](#tca13144-bib-0024){ref-type="ref"} the dissection of which has been widely accepted in Japan.[9](#tca13144-bib-0009){ref-type="ref"}Our study revealed that the prognostic impact of supraclavicular node metastasis in UTEC was similar to that of regional or celiac node metastasis, which validates the subgrouping of regional nodes in the Japanese classification. Our study also coincides with a multi‐institutional study in which the prognostic impact of supraclavicular nodes was similar to that of regional nodes for thoracic esophageal cancer.[8](#tca13144-bib-0008){ref-type="ref"} Meanwhile, we showed that LTEC involving supraclavicular nodes resulted in significantly worse prognoses compared with those involving previously designated regional or celiac nodes, which supports the reclassification of regional nodes.

Although the outcomes of LTEC with celiac node metastasis were relatively worse than those with regional node metastasis, our data revealed no statistically significance between them. Moreover, celiac node metastasis was not an independent predictor of worse OS and CSS in either UTEC or LTEC. Our findings justify the reclassification of celiac node metastasis into the N parameter in seventh and eighth editions of the AJCC staging system which is consistent with other studies.[16](#tca13144-bib-0016){ref-type="ref"}, [18](#tca13144-bib-0018){ref-type="ref"}, [28](#tca13144-bib-0028){ref-type="ref"}

Several studies[7](#tca13144-bib-0007){ref-type="ref"}, [19](#tca13144-bib-0019){ref-type="ref"}, [29](#tca13144-bib-0029){ref-type="ref"} have reported that treatment on esophageal cancer with supraclavicular node metastasis has been mainly palliative but not curative. However, other studies have demonstrated that surgery can benefit the prognosis of thoracic esophageal cancer with supraclavicular node metastasis.[5](#tca13144-bib-0005){ref-type="ref"}, [6](#tca13144-bib-0006){ref-type="ref"}, [18](#tca13144-bib-0018){ref-type="ref"}, [28](#tca13144-bib-0028){ref-type="ref"} In addition, up to 20% of patients with supraclavicular node metastasis showed reasonable survival after chemoradiation and surgical resection.[14](#tca13144-bib-0014){ref-type="ref"} From our data, surgery, chemotherapy and radiation were predictors of prolonged OS and CSS in both UTEC and LTEC, consistent with previous studies.[8](#tca13144-bib-0008){ref-type="ref"}, [14](#tca13144-bib-0014){ref-type="ref"} Meanwhile, our subgroup analysis indicated both surgery and radiotherapy were associated with better outcomes in LTEC with supraclavicular or celiac node metastasis. Our findings were also supported to some extent by studies which demonstrated that postoperative radiotherapy could not only improve the survival of stage II--III esophageal cancer irrespective of the tumor location, but also control local‐regional LTEC with supraclavicular nodeinvolvement.[2](#tca13144-bib-0002){ref-type="ref"}, [30](#tca13144-bib-0030){ref-type="ref"} Given that surgery could not improve prognoses of UTEC with either supraclavicular or celiac node metastasis, radiotherapy nonetheless exhibited its value in improving prognoses of UTEC. Our data thus indicate different therapeutic strategies should be considered according to the primary location of esophageal cancer.

We must acknowledge several limitations of this study. First, potential biases were inevitable because of the retrospective nature of our study. Although some advanced statistical methods were applied to balance the covariates among the arms, there were still some latent biases. Another potential criticism of the present study is that most patients included with UTEC had squamous cell carcinoma, whereas the majority of patients with LTEC had adenocarcinoma. The different main histology types might affect the therapeutic roles of surgery and radiotherapy. Also, compared with those without surgical resection, fewer UTEC patients with celiac node or supraclavicular node metastasis received surgery, which might affect the statistical power of our results. Furthermore, in the present study, patients diagnosed with upper esophageal cancer were more likely to have T4 stage and were less likely to receive surgery, which means this entity might be treated with less curative intent. However, according to the NCCN guideline, even for those with inoperable disease, surgical resection can also be considered for select patients.[31](#tca13144-bib-0031){ref-type="ref"} Moreover, the primary aim of this study was to evaluate the prognostic significance of supraclavicular and celiac lymph node metastasis. The large sample size of our study (especially those diagnosed with esophageal cancer located in the lower third) made our conclusion convincible. As a final comment, the SEER database could only provide a small number of thoracic esophageal cancer patients with supraclavicular node metastasis who underwent surgery. Large‐scale prospective randomized trials are needed to further validate our findings and better define the regional lymph nodes linked to tumor location.

In summary, our results provide preliminary evidence that the clinical significance of supraclavicular and celiac lymph node metastases should be reevaluated in thoracic esophageal cancer utilizing different prognostic information according to the primary sites.
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